Clinical Trials Logo

Influenza, Human clinical trials

View clinical trials related to Influenza, Human.

Filter by:

NCT ID: NCT00542776 Completed - Clinical trials for Inflammatory Bowel Disease (IBD)

Impact of Immunosuppression in IBD Patients on Response to Influenza Vaccine

Start date: October 2007
Phase: N/A
Study type: Observational

The purpose of this study is to compare the efficacy and safety of influenza vaccine in patients with inflammatory bowel disease (IBD) on immunosuppressive therapy with IBD patients on aminosalicylates and healthy historical controls.

NCT ID: NCT00540592 Completed - Influenza Clinical Trials

Immunogenicity and Safety Study to Evaluate Different Formulations of GSK Biologicals' Influenza Vaccine GSK576389A

Start date: October 8, 2007
Phase: Phase 2
Study type: Interventional

In order to find the formulation leading to a maximal increase of the immune response while maintaining an acceptable safety profile, this study is designed to evaluate the immunogenicity, safety and reactogenicity of the different formulations of GSK Biologicals' influenza vaccine administered in adults aged 65 years and older compared to Fluarix.

NCT ID: NCT00540228 Completed - Influenza Clinical Trials

Study to Evaluate an Influenza Vaccine Candidate

Start date: October 5, 2007
Phase: Phase 2
Study type: Interventional

In order to find the formulation leading to a maximal increase of the immune response while maintaining an acceptable safety profile, this study is designed to evaluate the immunogenicity, safety and reactogenicity of the different formulations of GSK Biologicals' influenza vaccine administered in adults aged 18-64 years.

NCT ID: NCT00539981 Completed - Influenza Clinical Trials

Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok

Start date: September 15, 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate a single dose of FluBlok in terms of safety, efficacy and effectiveness in prevention of influenza and influenza-like illness and assess clinical lot-to-lot consistency in manufacturing by evaluating and comparing the immunogenicity of three different lots of FluBlok in a subset of participants.

NCT ID: NCT00539864 Completed - Influenza Clinical Trials

Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV

Start date: September 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate and compare the safety, reactogenicity, immunogenicity, relative efficacy and effectiveness of FluBlok to a licensed trivalent influenza vaccine (TIV)in healthy adults age 50-64 years.

NCT ID: NCT00538512 Completed - Influenza Clinical Trials

Comparative Study of Influenza Vaccines in Adults, FLUVACS-year 4

FLUVACS
Start date: September 2007
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the absolute (versus placebo) and relative (one vaccine compared to the other) efficacies of the live attenuated and inactivated influenza vaccines in preventing laboratory confirmed symptomatic influenza caused by circulating strains whether similar or dissimilar to strains included in the vaccines.

NCT ID: NCT00538473 Completed - Influenza Clinical Trials

Evaluate Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults

Start date: October 23, 2007
Phase: Phase 2
Study type: Interventional

Since influenza vaccines are administered every year because of the frequent change in their antigenic composition, the safety and immunogenicity profile of GSK Biologicals' influenza vaccine GSK576389A will be re-evaluated after repeated vaccine administration. In this study, the subjects previously enrolled in study 107973 will receive a dose with the 2007-2008 season's formulations of Fluarix or GSK576389A. Only subjects who were previously enrolled in study 107973 (NCT00386113) are eligible for participation in this study.

NCT ID: NCT00538213 Completed - Influenza Clinical Trials

Evaluation of Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults

Start date: October 15, 2007
Phase: Phase 2
Study type: Interventional

Since influenza vaccines are administered every year because of the frequent change in their antigenic composition, the safety and immunogenicity profile of GSK Biologicals' influenza vaccine GSK576389A will be re-evaluated after repeated vaccine administration. In this study, the subjects previously enrolled in study 104887 will receive a dose with the 2007-2008 season's formulations of Fluarix or GSK576389A. Only subjects who were previously enrolled in study 104887 are eligible for participation in this study.

NCT ID: NCT00537524 Completed - Clinical trials for Prophylaxis of Avian Influenza

Immunogenicity, Safety and Tolerability of Two Doses of a Pre-pandemic Influenza Vaccine in Participants Aged 6 Months to 17 Years

Start date: September 2007
Phase: Phase 2
Study type: Interventional

Evaluate the immune response and reactogenicity of H5N1 vaccination in subjects aged 6 months to 17 years compared to seasonal flu vaccination

NCT ID: NCT00535665 Completed - Prevention Clinical Trials

Safety and Immunogenicity of an Inactivated Pandemic Influenza Vaccine

Start date: September 2007
Phase: Phase 2
Study type: Interventional

A single center, randomized and double-blind phase II clinical trial is to be conducted in adults to evaluate the safety and immunogenicity of an inactivated pandemic influenza vaccine (whole-virion, aluminium-adjuvanted).